1
|
Urcan AC, Criste AD, Szanto KI, Ștefan R, Zahan M, Muscă AS, Focsan M, Burtescu RF, Olah NK. Antimicrobial and Antiproliferative Activity of Green Synthesized Silver Nanoparticles Using Bee Bread Extracts. Pharmaceutics 2023; 15:1797. [PMID: 37513984 PMCID: PMC10383293 DOI: 10.3390/pharmaceutics15071797] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 06/15/2023] [Accepted: 06/20/2023] [Indexed: 07/30/2023] Open
Abstract
Bee bread (BB) is a fermented mixture of bee pollen, is rich in proteins, amino acids, fatty acids, polyphenols, flavonoids, as well as other bioactive compounds, and is considered functional food for humans. In this study, we explored an innovative green synthesis of colloidal silver nanoparticles, using BB extracts as reducing and stabilizing agents. A preliminary chemical characterization of the BB extracts was conducted. The plasmonic response of the as-synthesized silver nanoparticles (BB-AgNPs) was evaluated by UV-Vis spectroscopy, while their hydrodynamic diameter and zeta potential were investigated by dynamic light spectroscopy (DLS). Transmission electron microscopy (TEM) analysis pointed out polydisperse NPs with quasi-spherical shapes. The newly synthesized nanoparticles showed good antioxidant activity against the tested free radicals, DPPH, ABTS•+, and FRAP, the best results being obtained in the case of ABTS•+. BB-AgNPs exhibited good antibacterial activity on the tested Gram-positive and Gram-negative bacterial strains: herein S. aureus, B. cereus, E. faecalis, E. coli, P. aeruginosa, S. enteritidis, and on yeast C. albicans, respectively. The inhibition diameters varied between 7.67 ± 0.59 and 22.21 ± 1.06 mm, while the values obtained for minimum inhibitory concentration varied between 0.39 and 6.25 µg/mL. In vitro antiproliferative activity was tested on colon adenocarcinoma, ATCC HTB-37 cell line, and the results have shown that the green synthetized BB-AgNPs induced a substantial decrease in tumor cell viability in a dose-dependent manner with an IC50 ranging from 24.58 to 67.91 µg/mL. Consequently, more investigation is required to comprehend the processes of the cytotoxicity of AgNPs and develop strategies to mitigate their potentially harmful effects while harnessing their antimicrobial properties.
Collapse
Affiliation(s)
- Adriana Cristina Urcan
- Faculty of Animal Science and Biotechnologies, University of Agricultural Sciences and Veterinary Medicine, 3-5 Mănăştur Street, 400372 Cluj-Napoca, Romania
| | - Adriana Dalila Criste
- Faculty of Animal Science and Biotechnologies, University of Agricultural Sciences and Veterinary Medicine, 3-5 Mănăştur Street, 400372 Cluj-Napoca, Romania
| | - Karina Ioana Szanto
- Faculty of Animal Science and Biotechnologies, University of Agricultural Sciences and Veterinary Medicine, 3-5 Mănăştur Street, 400372 Cluj-Napoca, Romania
| | - Razvan Ștefan
- Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, 400372 Cluj-Napoca, Romania
| | - Marius Zahan
- Faculty of Animal Science and Biotechnologies, University of Agricultural Sciences and Veterinary Medicine, 3-5 Mănăştur Street, 400372 Cluj-Napoca, Romania
| | - Adriana Sebastiana Muscă
- Faculty of Animal Science and Biotechnologies, University of Agricultural Sciences and Veterinary Medicine, 3-5 Mănăştur Street, 400372 Cluj-Napoca, Romania
| | - Monica Focsan
- Nanobiophotonics and Laser Microspectroscopy Center, Interdisciplinary Research Institute in Bio-Nano-Sciences, Babes-Bolyai University, Treboniu Laurian No. 42, 400271 Cluj-Napoca, Romania
| | | | - Neli Kinga Olah
- PlantExtrakt Ltd., Rădaia, 407059 Cluj-Napoca, Romania
- Faculty of Pharmacy, "Vasile Goldiş" Western University of Arad, 310414 Arad, Romania
| |
Collapse
|
2
|
Elbagory AM, Hull R, Meyer M, Dlamini Z. Reports of Plant-Derived Nanoparticles for Prostate Cancer Therapy. PLANTS (BASEL, SWITZERLAND) 2023; 12:plants12091870. [PMID: 37176928 PMCID: PMC10181082 DOI: 10.3390/plants12091870] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Revised: 04/18/2023] [Accepted: 04/28/2023] [Indexed: 05/15/2023]
Abstract
Plants have demonstrated potential in providing various types of phytomedicines with chemopreventive properties that can combat prostate cancer. However, despite their promising in vitro activity, the incorporation of these phytochemicals into the market as anticancer agents has been hindered by their poor bioavailability, mainly due to their inadequate aqueous solubility, chemical instability, and unsatisfactory circulation time. To overcome these drawbacks, it has been suggested that the incorporation of phytochemicals as nanoparticles can offer a solution. The use of plant-based chemicals can also improve the biocompatibility of the formulated nanoparticles by avoiding the use of certain hazardous chemicals in the synthesis, leading to decreased toxicity in vivo. Moreover, in some cases, phytochemicals can act as targeting agents to tumour sites. This review will focus on and summarize the following points: the different types of nanoparticles that contain individual phytochemicals or plant extracts in their design with the aim of improving the bioavailability of the phytochemicals; the therapeutic evaluation of these nanoparticles against prostate cancer both in vitro and in vivo and the reported mode of action and the different types of anticancer experiments used; how the phytochemicals can also improve the targeting effects of these nanoparticles in some instances; and the potential toxicity of these nanoparticles.
Collapse
Affiliation(s)
- Abdulrahman M Elbagory
- Department of Science and Innovation (DSI)/Mintek Nanotechnology Innovation Centre (NIC), Biolabels Research Node, Department of Biotechnology, University of the Western Cape, Cape Town, Private Bag X17, Bellville 7535, South Africa
| | - Rodney Hull
- SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield 0028, South Africa
| | - Mervin Meyer
- Department of Science and Innovation (DSI)/Mintek Nanotechnology Innovation Centre (NIC), Biolabels Research Node, Department of Biotechnology, University of the Western Cape, Cape Town, Private Bag X17, Bellville 7535, South Africa
| | - Zodwa Dlamini
- SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield 0028, South Africa
| |
Collapse
|
3
|
Pham Le Khanh H, Nemes D, Rusznyák Á, Ujhelyi Z, Fehér P, Fenyvesi F, Váradi J, Vecsernyés M, Bácskay I. Comparative Investigation of Cellular Effects of Polyethylene Glycol (PEG) Derivatives. Polymers (Basel) 2022; 14:279. [PMID: 35054686 PMCID: PMC8779311 DOI: 10.3390/polym14020279] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 01/03/2022] [Accepted: 01/07/2022] [Indexed: 12/11/2022] Open
Abstract
Nowadays, polyethylene glycols referred to as PEGs are widely used in cosmetics, consumer care products, and the pharmaceutical industry. Their advantageous properties such as chemical stability, low immunogenicity, and high tolerability explain why PEGs are applied in many fields of pharmaceutical formulations including parenteral, topical, ophthalmic, oral, and rectal preparations and also in modern drug delivery systems. Given their extensive use, they are considered a well-known group of chemicals. However, the number of large-scale comparative studies involving multiple PEGs of wide molecular weight range is low, as in most cases biological effects are estimated upon molecular weight. The aim of this publication was to study the action of PEGs on Caco-2 cells and G. mellonella larvae and to calculate the correlation of these effects with molecular weight and osmolality. Eleven PEGs of different molecular weight were used in our experiments: PEG 200, PEG 300, PEG 400, PEG 600, PEG 1000, PEG 1500, PEG 4000, PEG 8000, PEG 10,000, 12,000, and PEG 20,000. The investigated cellular effects included cytotoxicity (MTT and Neutral Red assays, flow cytometry with propidium iodide and annexin V) and autophagy. The osmolality of different molecular weight PEGs with various concentrations was measured by a vapor pressure osmometer OSMOMAT 070 and G. mellonella larvae were injected with the solutions of PEGs. Sorbitol was used as controls of the same osmolality. Statistical correlation was calculated to describe the average molecular weight dependence of the different measured effects. Osmolality, the cytotoxicity assays, flow cytometry data, and larvae mortality had significant correlation with the structure of the PEGs, while autophagosome formation and the proportion of early apoptotic cells showed no statistical correlation. Overall, it must be noted that PEGs must be tested individually for biological effects as not all effects can be estimated by the average molecular weight.
Collapse
Affiliation(s)
- Ha Pham Le Khanh
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary; (H.P.L.K.); (D.N.); (Á.R.); (Z.U.); (P.F.); (F.F.); (J.V.); (M.V.)
- Doctorate School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
- Institute of Healthcare Industry, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
| | - Dániel Nemes
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary; (H.P.L.K.); (D.N.); (Á.R.); (Z.U.); (P.F.); (F.F.); (J.V.); (M.V.)
- Doctorate School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
| | - Ágnes Rusznyák
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary; (H.P.L.K.); (D.N.); (Á.R.); (Z.U.); (P.F.); (F.F.); (J.V.); (M.V.)
- Doctorate School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
- Institute of Healthcare Industry, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
| | - Zoltán Ujhelyi
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary; (H.P.L.K.); (D.N.); (Á.R.); (Z.U.); (P.F.); (F.F.); (J.V.); (M.V.)
- Doctorate School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
| | - Pálma Fehér
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary; (H.P.L.K.); (D.N.); (Á.R.); (Z.U.); (P.F.); (F.F.); (J.V.); (M.V.)
- Doctorate School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
| | - Ferenc Fenyvesi
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary; (H.P.L.K.); (D.N.); (Á.R.); (Z.U.); (P.F.); (F.F.); (J.V.); (M.V.)
- Doctorate School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
| | - Judit Váradi
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary; (H.P.L.K.); (D.N.); (Á.R.); (Z.U.); (P.F.); (F.F.); (J.V.); (M.V.)
- Doctorate School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
| | - Miklós Vecsernyés
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary; (H.P.L.K.); (D.N.); (Á.R.); (Z.U.); (P.F.); (F.F.); (J.V.); (M.V.)
- Doctorate School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
| | - Ildikó Bácskay
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary; (H.P.L.K.); (D.N.); (Á.R.); (Z.U.); (P.F.); (F.F.); (J.V.); (M.V.)
- Doctorate School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
- Institute of Healthcare Industry, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
| |
Collapse
|